Medical/Pharmaceuticals
ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally
SINGAPORE, July 25, 2024 /PRNewswire/ -- ObvioHealth
Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot
Uplifting pharmacists' role in primary care and positioning pharmacies as essential care destinations in local communities CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ -- MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software tra...
SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study
SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE
approval, initiating the global THRIVE study in US,Europe and Israel
TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie
Corero Network Security Announces H1 Financial Results
Company posts 16% YoY growth with increases in ARR and bookings LONDON, July 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced its financial results for the first half of 2024. The company ...
deCODE genetics: Variants in the genome affect DNA methylation
REYKJAVIK, Iceland, July 24, 2024 /PRNewswire/ -- A new study by scientists at deCODE Genetics, subsidiary of Amgen, shows that sequence variants drive the correlation between DNA methylation and gene expression. The same variants are linked to various diseases as well as other human traits. ...
For the First time in Thailand! Chulalongkorn University Researchers Found a "Glowing Land Snail"
BANGKOK, July 24, 2024 /PRNewswire/ -- Chulalongkorn University
Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services
Aragen Life Sciences Ltd. excels in providing end-to-end drug discovery and development solutions, showcasing its innovative approaches and strong commitment to sustainability and customer satisfaction. SAN ANTONIO, July 24, 2024 /PRNewswire/ -- Frost & Sullivan has recognized Aragen Life Scienc...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...
Telix Successfully Prices A$650 Million Convertible Bonds
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...
ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution
ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling universal, language-free usage for fast and accurate results. SAN ANTONIO, July 23, 2024 /PRNewswire/ -- Frost & Sullivan recently analyzed the brain, m...
Telix Announces A$600 Million Convertible Bonds Offering
MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...
SND Introduces Revolutionary Moderated Drinking Treatment Program
TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...
Linical Named Best Global CRO by Global Health & Pharma Magazine
OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title ofBest Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence A...
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs
SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
* Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials * Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, l...
Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
* Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) * Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net a...
Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency
SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...
Agilent Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit
SINGAPORE, July 22, 2024 /PRNewswire/ -- Agilent Technologies Inc.
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis
SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01